

Themis Medicare unveils VIRALEX to treat COVID-19 variants

28 June 2022 | News

The drug, available in 500 mg tablet form, has been approved by DCGI



Mumbai-based Themis Medicare has launched VIRALEX- Inosine Pranobex to treat COVID-19, which is effective irrespective of the new variants. The benefit of VIRALEX is that it is effective not just in COVID-19 but also in other viral respiratory infections.

The safety and efficacy have been demonstrated through a double-blind, randomised placebo-control (considered a gold standard in clinical research) multicentre trial in India with the drug showing significantly early clinical response and cure.

The trials were conducted during the Delta wave of COVID-19 and showed early improvement and complete relief from symptoms in patients who received VIRALEX.

The oral medication is available in the form of a 500 mg tablet.

VIRALEX- Inosine Pranobex has been approved for the treatment of influenza and other Acute Viral Respiratory Infections (AVRI) including COVID -19, mucocutaneous herpes, genital wart and Subacute Sclerosing Panencephalitis (SSPE) by the Drug Controller General of India (DCGI).